FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885654872> ?p ?o ?g. }

• W2885654872 abstract "Glioblastoma (GBM) is a uniformly fatal primary brain tumor, characterized by extensive cellular heterogeneity. Numerous studies have implicated CD133+ brain tumor initiating cells (BTICs) as drivers of chemo- and radio-resistance in GBM. We have recently demonstrated that a CD133-driven gene signature is predictive of poor overall survival and targeting CD133+ treatment-refractory cells may be an effective strategy to block GBM recurrence. Bispecific T-Cell engaging antibodies (BiTEs) and Chimeric antigen receptors (CARs) present promising immunotherapeutic approaches that have not yet been validated for recurrent GBM. Using CellectSeq, a novel methodology that combines the use of phage-displayed synthetic antibody libraries and DNA sequencing, we developed the CD133-specific monoclonal antibody ‘RW039. We constructed CD133-specific BiTEs that consist of two arms; one recognizes the tumor antigen (CD133) and the second is specific to the CD3 antigen that binds to human GBMs and PBMC-derived T cells, respectively. We observed BiTEs redirecting T cells to kill GBMs, with greater efficiency observed in CD133high GBMs, validating BiTE target specificity. Incubating T-cells with BiTEs and the CD133high GBMs resulted in increased expression of T cell activation markers. In parallel, we derived the single chain variable fragment (scFv) from RW03 we engineered a second-generation CAR T cell. CD133-specific CAR-T cells were cytotoxic to CD133+ GBMs. Co-culturing CD133 CAR-T cells with GBMs triggered T cell activation and proliferation. Treatment of GBM tumor-bearing mice with CD133-specific CAR-T cells yielded extended survival in mice and significant reductions in brain tumor burden. Furthermore, we uniquely adapted the existing chemoradiotherapy protocol for GBM patients for treatment of immunocompromised mice engrafted with human GBMs. Within this model, we have initiated treatment of recurrent GBM directed against CD133+ BTICs, to allow for a direct prospective comparison of toxicity and efficacy of BiTEs and CAR-T cell strategies. Citation Format: Parvez Vora, Jarrett Adams, Mohini Singh, Chitra Venugopal, Nazanin Tatari, Chirayu Chokshi, Maleeha Qazi, Sabra Salim, Sujeivan Mahendram, David Bakhshinyan, Max London, Neil Savage, Minomi Subapanditha, Nicole McFarlane, James Pan, Jonathan Bramson, Sachdev Sidhu, Jason Moffat, Sheila Singh. BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1763." @default.
• W2885654872 created "2018-08-22" @default.
• W2885654872 creator A5001141427 @default.
• W2885654872 creator A5002640598 @default.
• W2885654872 creator A5008471645 @default.
• W2885654872 creator A5012812751 @default.
• W2885654872 creator A5015278451 @default.
• W2885654872 creator A5022908319 @default.
• W2885654872 creator A5043563044 @default.
• W2885654872 creator A5044259899 @default.
• W2885654872 creator A5048722679 @default.
• W2885654872 creator A5063733303 @default.
• W2885654872 creator A5064672955 @default.
• W2885654872 creator A5064942199 @default.
• W2885654872 creator A5068526019 @default.
• W2885654872 creator A5076165905 @default.
• W2885654872 creator A5079616219 @default.
• W2885654872 creator A5079730813 @default.
• W2885654872 creator A5083723060 @default.
• W2885654872 creator A5086112491 @default.
• W2885654872 creator A5066230924 @default.
• W2885654872 date "2018-07-01" @default.
• W2885654872 modified "2023-10-04" @default.
• W2885654872 title "Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies" @default.
• W2885654872 doi "https://doi.org/10.1158/1538-7445.am2018-1763" @default.
• W2885654872 hasPublicationYear "2018" @default.
• W2885654872 type Work @default.
• W2885654872 sameAs 2885654872 @default.
• W2885654872 citedByCount "0" @default.
• W2885654872 crossrefType "proceedings-article" @default.
• W2885654872 hasAuthorship W2885654872A5001141427 @default.
• W2885654872 hasAuthorship W2885654872A5002640598 @default.
• W2885654872 hasAuthorship W2885654872A5008471645 @default.
• W2885654872 hasAuthorship W2885654872A5012812751 @default.
• W2885654872 hasAuthorship W2885654872A5015278451 @default.
• W2885654872 hasAuthorship W2885654872A5022908319 @default.
• W2885654872 hasAuthorship W2885654872A5043563044 @default.
• W2885654872 hasAuthorship W2885654872A5044259899 @default.
• W2885654872 hasAuthorship W2885654872A5048722679 @default.
• W2885654872 hasAuthorship W2885654872A5063733303 @default.
• W2885654872 hasAuthorship W2885654872A5064672955 @default.
• W2885654872 hasAuthorship W2885654872A5064942199 @default.
• W2885654872 hasAuthorship W2885654872A5066230924 @default.
• W2885654872 hasAuthorship W2885654872A5068526019 @default.
• W2885654872 hasAuthorship W2885654872A5076165905 @default.
• W2885654872 hasAuthorship W2885654872A5079616219 @default.
• W2885654872 hasAuthorship W2885654872A5079730813 @default.
• W2885654872 hasAuthorship W2885654872A5083723060 @default.
• W2885654872 hasAuthorship W2885654872A5086112491 @default.
• W2885654872 hasConcept C142724271 @default.
• W2885654872 hasConcept C147483822 @default.
• W2885654872 hasConcept C154317977 @default.
• W2885654872 hasConcept C159654299 @default.
• W2885654872 hasConcept C202751555 @default.
• W2885654872 hasConcept C203014093 @default.
• W2885654872 hasConcept C2776090121 @default.
• W2885654872 hasConcept C2777701055 @default.
• W2885654872 hasConcept C2778227246 @default.
• W2885654872 hasConcept C2779130545 @default.
• W2885654872 hasConcept C2780674031 @default.
• W2885654872 hasConcept C3875195 @default.
• W2885654872 hasConcept C502942594 @default.
• W2885654872 hasConcept C542903549 @default.
• W2885654872 hasConcept C55493867 @default.
• W2885654872 hasConcept C71924100 @default.
• W2885654872 hasConcept C86803240 @default.
• W2885654872 hasConcept C8891405 @default.
• W2885654872 hasConceptScore W2885654872C142724271 @default.
• W2885654872 hasConceptScore W2885654872C147483822 @default.
• W2885654872 hasConceptScore W2885654872C154317977 @default.
• W2885654872 hasConceptScore W2885654872C159654299 @default.
• W2885654872 hasConceptScore W2885654872C202751555 @default.
• W2885654872 hasConceptScore W2885654872C203014093 @default.
• W2885654872 hasConceptScore W2885654872C2776090121 @default.
• W2885654872 hasConceptScore W2885654872C2777701055 @default.
• W2885654872 hasConceptScore W2885654872C2778227246 @default.
• W2885654872 hasConceptScore W2885654872C2779130545 @default.
• W2885654872 hasConceptScore W2885654872C2780674031 @default.
• W2885654872 hasConceptScore W2885654872C3875195 @default.
• W2885654872 hasConceptScore W2885654872C502942594 @default.
• W2885654872 hasConceptScore W2885654872C542903549 @default.
• W2885654872 hasConceptScore W2885654872C55493867 @default.
• W2885654872 hasConceptScore W2885654872C71924100 @default.
• W2885654872 hasConceptScore W2885654872C86803240 @default.
• W2885654872 hasConceptScore W2885654872C8891405 @default.
• W2885654872 hasLocation W28856548721 @default.
• W2885654872 hasOpenAccess W2885654872 @default.
• W2885654872 hasPrimaryLocation W28856548721 @default.
• W2885654872 hasRelatedWork W2020590412 @default.
• W2885654872 hasRelatedWork W2038453122 @default.
• W2885654872 hasRelatedWork W2052457630 @default.
• W2885654872 hasRelatedWork W2156140358 @default.
• W2885654872 hasRelatedWork W2347738878 @default.
• W2885654872 hasRelatedWork W2413922971 @default.
• W2885654872 hasRelatedWork W2587658576 @default.
• W2885654872 hasRelatedWork W2791145324 @default.
• W2885654872 hasRelatedWork W4224119345 @default.
• W2885654872 hasRelatedWork W4229455221 @default.
• W2885654872 isParatext "false" @default.
• W2885654872 isRetracted "false" @default.

• next